The Impact of the COVID-19 Pandemic on Cancer Patient's Management-Lithuanian Cancer Center Experience.

COVID-19 pandemic cancer management national lockdown

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
09 Nov 2021
Historique:
received: 09 09 2021
revised: 31 10 2021
accepted: 04 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

The pandemic spread of the COVID-19 virus significantly affected daily life, but the highest pressure was piled on the health care system. Our aim was to evaluate an impact of COVID-19 pandemic management measures on cancer services at the National Cancer Institute (NCI) of Lithuania. We assessed the time period from 1 February 2020 to 31 December 2020 and compared it to the same period of 2019. Data for our analysis were extracted from the NCI Hospital Information System (HIS) and the National Health Insurance Fund (NHIF). Contingency table analysis and ANOVA were performed. The COVID-19 pandemic negatively affected the cancer services provided by NCI. Reductions in diagnostic radiology (-16%) and endoscopy (-29%) procedures were accompanied by a decreased number of patients with ongoing medical (-30%), radiation (-6%) or surgical (-10%) treatment. The changes in the number of newly diagnosed cancer patients were dependent on tumor type and disease stage, showing a rise in advanced disease at diagnosis already during the early period of the first lockdown. The extent of out-patient consultations (-14%) and disease follow-up visits (-16%) was also affected by the pandemic, and only referrals to psychological/psychiatric counselling were increased. Additionally, the COVID-19 pandemic had an impact on the structure of cancer services by fostering the application of modified systemic anticancer therapy or hypofractionated radiotherapy. The most dramatic drop occurred in the number of patients participating in cancer prevention programs; the loss was 25% for colon cancer and 62% for breast cancer screening. Marked restriction in access to preventive cancer screening and overall reduction of the whole spectrum of cancer services may negatively affect cancer survival measures in the nearest future.

Identifiants

pubmed: 34828568
pii: healthcare9111522
doi: 10.3390/healthcare9111522
pmc: PMC8623620
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

ESMO Open. 2021 Jun;6(3):100134
pubmed: 33984676
Cancer Biol Med. 2021 Feb 15;18(1):298-307
pubmed: 33628602
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):631-640
pubmed: 32589990
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
BMJ. 2021 May 7;373:n1179
pubmed: 33962972
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Patient Educ Couns. 2020 Mar;103(3):607-616
pubmed: 31753521
BMJ. 2020 Jul 15;370:m2747
pubmed: 32669352
JCO Clin Cancer Inform. 2020 Nov;4:1059-1071
pubmed: 33253013
Hematol Oncol Stem Cell Ther. 2020 Jul 30;:
pubmed: 32745466
JAMA Oncol. 2020 Oct 1;6(10):1630-1632
pubmed: 32789489
Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281
pubmed: 32241520
PLoS One. 2014 Dec 02;9(12):e114028
pubmed: 25461959
J Am Coll Surg. 2020 Oct;231(4):434-447.e2
pubmed: 32771654
Int J Colorectal Dis. 2020 Oct;35(10):1951-1954
pubmed: 32500432
Int J Environ Res Public Health. 2021 Feb 26;18(5):
pubmed: 33652949
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
Radiol Clin North Am. 2021 Jan;59(1):1-11
pubmed: 33222992
PLoS One. 2019 Mar 1;14(3):e0213209
pubmed: 30822350
Adv Radiat Oncol. 2020 Oct 29;5(Suppl 1):26-32
pubmed: 33145460

Auteurs

Daiva Dabkeviciene (D)

Biobank, National Cancer Institute, 08406 Vilnius, Lithuania.

Ieva Vincerzevskiene (I)

Cancer Registry, National Cancer Institute, 08406 Vilnius, Lithuania.
Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.

Vincas Urbonas (V)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Department of Medical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.

Jonas Venius (J)

Department of Medical Physics, National Cancer Institute, 08406 Vilnius, Lithuania.

Audrius Dulskas (A)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Department of General and Abdominal Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Birute Brasiuniene (B)

Biobank, National Cancer Institute, 08406 Vilnius, Lithuania.
Department of Medical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.

Ernestas Janulionis (E)

Department of Brachyterapy, National Cancer Institute, 08406 Vilnius, Lithuania.

Arvydas Burneckis (A)

Department of Radiation Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.

Asta Zileviciene (A)

Department of External Beam Radiotherapy, National Cancer Institute, 08406 Vilnius, Lithuania.

Sigitas Tiskevicius (S)

Department of Nuclear Medicine, National Cancer Institute, 08406 Vilnius, Lithuania.

Rasa Vanseviciute-Petkeviciene (R)

Outpatients Department, National Cancer Institute, 08406 Vilnius, Lithuania.

Jurgita Usinskiene (J)

Department of Radiology, National Cancer Institute, 08406 Vilnius, Lithuania.

Ruta Briediene (R)

Department of Radiology, National Cancer Institute, 08406 Vilnius, Lithuania.

Giedre Bulotiene (G)

Outpatients Department, National Cancer Institute, 08406 Vilnius, Lithuania.

Eugenijus Stratilatovas (E)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Department of General and Abdominal Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Valerijus Ostapenko (V)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Department of Breast Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Jolita Gibaviciene (J)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Department of ENT, Head and Neck Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Ignas Karnas (I)

Department of ENT, Head and Neck Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Saule Kekstaite (S)

Department of ENT, Head and Neck Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Jurgita Navickiene (J)

Department of ENT, Head and Neck Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Albertas Ulys (A)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Department of Oncourology, National Cancer Institute, 08406 Vilnius, Lithuania.

Algirdas Zalimas (A)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Outpatients Department, National Cancer Institute, 08406 Vilnius, Lithuania.

Algimantas Sruogis (A)

Department of Oncourology, National Cancer Institute, 08406 Vilnius, Lithuania.

Zygimantas Kardelis (Z)

Department of Oncourology, National Cancer Institute, 08406 Vilnius, Lithuania.

Sigitas Zaremba (S)

Department of Thoracic Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Renatas Askinis (R)

Department of Thoracic Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Saulius Cicenas (S)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.
Department of Thoracic Surgery, National Cancer Institute, 08406 Vilnius, Lithuania.

Renatas Tikuisis (R)

Department of Anesthesiology and Intensive Care, National Cancer Institute, 08406 Vilnius, Lithuania.

Ruta Ciurliene (R)

Department of Oncogynecology, National Cancer Institute, 08406 Vilnius, Lithuania.

Sonata Jarmalaite (S)

Laboratory of Clinical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania.

Classifications MeSH